Last reviewed · How we verify
Encube Ethicals Pvt. Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Elimite™ Cream (permethrin) 5% | Elimite™ Cream (permethrin) 5% | phase 3 | Pyrethroid insecticide | Voltage-gated sodium channels | Dermatology / Parasitology | |
| Solaraze 3% Topical Gel | Solaraze 3% Topical Gel | phase 3 | retinoid | retinoic acid receptors | Dermatology |
Therapeutic area mix
- Dermatology · 1
- Dermatology / Parasitology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Actavis Inc. · 1 shared drug class
- Fougera Pharmaceuticals Inc. · 1 shared drug class
- Galderma R&D · 1 shared drug class
- Infectopharm Arzneimittel GmbH · 1 shared drug class
- Kowa Company, Ltd. · 1 shared drug class
- South Plains Oncology Consortium · 1 shared drug class
- Stiefel, a GSK Company · 1 shared drug class
- Teva Pharmaceuticals USA · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Encube Ethicals Pvt. Ltd.:
- Encube Ethicals Pvt. Ltd. pipeline updates — RSS
- Encube Ethicals Pvt. Ltd. pipeline updates — Atom
- Encube Ethicals Pvt. Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Encube Ethicals Pvt. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/encube-ethicals-pvt-ltd. Accessed 2026-05-16.